UNIV. MILAN

Pharmaceutical Science, and Pharmacological and Biomolecular Science Departments, Italy  (Coordinating University)

UNIV. ABERDEEN

Institute of Medical Science, School of Medicine, Medical Science and Nutrition, UK

UNIV. ANTWERP

Laboratory of Physiopharmacology, Belgium

UNIV. BARCELONA

Department of Biochemistry and Molecular Biology, Spain

UNIV. LEIDEN

Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine, The Netherlands

TOGETHER

Marie Skłodowska-Curie ITN-European Joint Doctorate

UPCOMING EVENT

MOGLYNET CAREER WORKSHOP

LUMC – Leiden University Medical Center, Netherlands

April 11st - 13th, 2018

Marie Skłodowska-Curie ITN-European Joint Doctorate

MOGLYNET-PhD programme in drug discovery and development

The Horizon 2020 MSCA joint doctoral project MoGglyNet (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is running by a Consortium of Universities in cooperation with Pharma Industries and Associations. The programme was established with the aim of providing 12 Early Stage Researchers with innovative PhD trainings in Drug Discovery and Development.

Latest news about MOGLYNET

An article published in

Impact Publication - Future Proofing Medical R&D

October 2017

IMPACTPUBLICATION_cropped

Click here for the complete volume (page 28-30)

HOW IT WORKS

The MOGLYNET PhD programme aims to define a new joint PhD educational model in Drug Discovery and Development and to promote institutional cooperation and mobility.

An active contribution of Industry in training activities is an important feature of the programme. The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. These includes computational chemistry, chemical synthesis, bioanalytics, biophysics, in vitro biological evaluations, in vivo studies, imaging, metabolomics, proteomics, and oxidative stress studies.

OUR PARTNERS

WE SEE THE FUTURE

MOGLYNET IN NUMBERS
0
UNIVERSITIES
0
INDUSTRIAL PARTNERS
0
EUROPEAN ASSOCIATIONS
0
PhD FELLOWSHIPS

WHAT WE THINK ABOUT MOGLYNET

  • Dr.ssa Anni Svala
    Dr.ssa Anni Svala

    The non-academic contribution provides the way forward to help academia in meeting the educational needs of pharmaceutical industry.

  • Prof.ssa Marina Carini
    Prof.ssa Marina Carini

    The exposure of recruited researchers to different environments is specifically designed to integrate and complement the sectorial knowledge of the fellow allowing the creation of a common knowledge and language for ESRs.

  • Dr. Stefano Bellosta
    Dr. Stefano Bellosta

    Synergy between all the participants is fundamental to reach the goals planned by MOGLYNET programme.

  • Prof. Matteo Zanda
    Prof. Matteo Zanda

    MOGLYNET EJD stems from six Doctoral Courses/Schools at the five beneficiary institutions providing research and training in the field of drug discovery and health. A double degree in Drug Discovery and Development will be delivered by two Accademic beneficiaries.

  • Dr.ssa Mirela Delibegovic
    Dr.ssa Mirela Delibegovic

    The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary (from molecular modelling to in vivo studies) and will involve a number of different state-of-the-art technologies and methodologies.

  • Prof. Guido De Meyer
    Prof. Guido De Meyer

    We are a consortium of excellence in the atherosclerosis field. The research strategy proposed by MOGLYNET to takle atherosclerosis, which is a major unmet medical need, is higly original and innovative.

  • Prof. Paul Quax
    Prof. Paul Quax

    Atherosclerotic cardiovascular disease is a disease of aging and is the major cause of death in the western world and for this reason there is a strong high need for additional pharmacological interventions.

  • Prof. Francesca Clerici
    Prof. Francesca Clerici

    The European Commission has identified active and healthy aging as a major societal challenge common to all European countries, and an area which presents considerable potential for Europe to lead the world in providing innovative responses to this challenge.

  • Prof. Maria Luisa Gelmi
    Prof. Maria Luisa Gelmi

    The transfer of “what” a researcher know in “how” to realize this in a complex system related to the drug is not trivial and requires a wide overall view of the problem. The mission of MOGLYNET is to define a joint doctorate educational training model where Academia and Industry Join their forces to reach this target.

color
http://www.moglynet.com/website/wp-content/themes/yunik-installable/
http://www.moglynet.com/website/
#E72E4E
style1
scrollauto
Loading posts...
#A0A0A0
on
none
loading
#A0A0A0
Sort Gallery
http://www.moglynet.com/website/wp-content/themes/yunik-installable
on
yes
yes
off
on
Your e.mail
off
off